Literature DB >> 19711108

Metamorphopsia in patients with macular telangiectasia type 2.

Peter Charbel Issa1, Frank G Holz, Hendrik P N Scholl.   

Abstract

PURPOSE: To assess metamorphopsia in patients with macular telangiectasia (MacTel) type 2.
METHODS: In a prospective observational cohort study, 40 eyes of 20 patients with MacTel type 2 were investigated by funduscopy, fluorescein angiography, optical coherence tomography and microperimetry. Metamorphopsia was assessed using Amsler grids following a standard protocol and standardized questionnaire.
RESULTS: Metamorphopsia was present in 30 (83%) out of 36 nonproliferative eyes and in all four eyes with neovascular membranes. In the 30 nonproliferative eyes with distortions, metamorphopsia was always present in the nasal quadrant of the central visual field. Distortions were most pronounced in the nasal and lower quadrant in 70 and 30%, respectively. Three nonproliferative eyes with a very early and three eyes with a late disease stage did not perceive metamorphopsia. The degree of distortions was often but not necessarily correlated with the degree of leakage. Metamorphopsia was present in five out of eight eyes with normal sensitivity in microperimetry testing. Detection of scotoma by Amsler grid testing was poor.
CONCLUSION: Metamorphopsia is a frequent clinical symptom in MacTel type 2 even in the absence of neovascularization. Since macular thickness was within normal limits in such eyes, extensive swelling or distortion of the neurosensory retina would not account for metamorphopsia in contrast to other macular diseases such as age-related macular degeneration or idiopathic epiretinal membranes.

Entities:  

Mesh:

Year:  2009        PMID: 19711108     DOI: 10.1007/s10633-009-9190-9

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  18 in total

1.  Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography.

Authors:  Lelia A Paunescu; Tony H Ko; Jay S Duker; Annie Chan; Wolfgang Drexler; Joel S Schuman; James G Fujimoto
Journal:  Ophthalmology       Date:  2005-12-15       Impact factor: 12.079

2.  Visual function and subjective quality of life compared in subjects with acquired macular disease.

Authors:  C A Hazel; K L Petre; R A Armstrong; M T Benson; N A Frost
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-05       Impact factor: 4.799

3.  Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis.

Authors:  Alain Gaudric; Ghislaine Ducos de Lahitte; Salomon Y Cohen; Pascale Massin; Belkacem Haouchine
Journal:  Arch Ophthalmol       Date:  2006-10

4.  Perceptual filling in of artificially induced scotomas in human vision.

Authors:  V S Ramachandran; R L Gregory
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

5.  Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia.

Authors:  Peter Charbel Issa; Hans-Martin Helb; Frank G Holz; Hendrik P N Scholl
Journal:  Am J Ophthalmol       Date:  2007-11-05       Impact factor: 5.258

6.  Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2.

Authors:  Robert P Finger; Peter Charbel Issa; Rolf Fimmers; Frank G Holz; Gary S Rubin; Hendrik P N Scholl
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-07       Impact factor: 4.799

7.  Patient selection for macular translocation surgery using the scanning laser ophthalmoscope.

Authors:  Gildo Y Fujii; Eugene de Juan; Janet Sunness; Mark S Humayun; Dante J Pieramici; Tom S Chang
Journal:  Ophthalmology       Date:  2002-09       Impact factor: 12.079

8.  Idiopathic juxtafoveolar retinal telangiectasis.

Authors:  J D Gass; R T Oyakawa
Journal:  Arch Ophthalmol       Date:  1982-05

9.  Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia.

Authors:  Steffen Schmitz-Valckenberg; Kristie Fan; Alex Nugent; Gary S Rubin; Tunde Peto; Adnan Tufail; Cathy Egan; Alan C Bird; Fred W Fitzke
Journal:  Arch Ophthalmol       Date:  2008-03

10.  Validity and interpretation of Amsler grid reports.

Authors:  R A Schuchard
Journal:  Arch Ophthalmol       Date:  1993-06
View more
  14 in total

1.  Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors:  Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

2.  Demographic features of idiopathic macular telangiectasia in Korean patients.

Authors:  Sung Hyun Kim; Jaeryung Oh; Soh-Eun Ahn; Choul Yong Park; Jong-Hyun Oh
Journal:  Korean J Ophthalmol       Date:  2015-05-20

3.  Prevalence and progression of pigment clumping associated with idiopathic macular telangiectasia type 2.

Authors:  Annal D Meleth; Brian C Toy; Divya Nigam; Elvira Agrón; Robert P Murphy; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2013-04       Impact factor: 4.256

4.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 5.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

6.  [Functional characteristics of macular telangiectasia type 2].

Authors:  T F C Heeren; E Krüger; F G Holz; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

7.  Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.

Authors:  Lydia Sauer; Rebekah H Gensure; Martin Hammer; Paul S Bernstein
Journal:  Ophthalmol Retina       Date:  2017-12-08

8.  Analysis of candidate genes for macular telangiectasia type 2.

Authors:  Nancy L Parmalee; Carl Schubert; Joanna E Merriam; Kaija Allikmets; Alan C Bird; Mark C Gillies; Tunde Peto; Maria Figueroa; Martin Friedlander; Marcus Fruttiger; John Greenwood; Stephen E Moss; Lois E H Smith; Carmel Toomes; Chris F Inglehearn; Rando Allikmets
Journal:  Mol Vis       Date:  2010-12-14       Impact factor: 2.711

Review 9.  Multimodality imaging in macular telangiectasia 2: A clue to its pathogenesis.

Authors:  Lihteh Wu
Journal:  Indian J Ophthalmol       Date:  2015-05       Impact factor: 1.848

10.  Identification of a potential susceptibility locus for macular telangiectasia type 2.

Authors:  Nancy L Parmalee; Carl Schubert; Maria Figueroa; Alan C Bird; Tunde Peto; Mark C Gillies; Paul S Bernstein; Krzysztof Kiryluk; Joseph D Terwilliger; Rando Allikmets
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.